|
1
|
Wilkinson L and Gathani T: Understanding breast cancer as a global health concern. Br J Radiol. 95:202110332022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sancho-Garnier H and Colonna M: Breast cancer epidemiology. Presse Med. 48:1076–1084. 2019.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50:332017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ullah MF: Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol. 1152:51–64. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kolak A, Kamińska M, Sygit K, Budny A, Surdyka D, Kukiełka-Budny B and Burdan F: Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 24:549–553. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang YN, Xia KR, Li CY, Wei BL and Zhang B: Review of breast cancer pathologigcal image processing. Biomed Res Int. 2021:19947642021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Varinska L, Gal P, Mojzisova G, Mirossay L and Mojzis J: Soy and breast cancer: Focus on angiogenesis. Int J Mol Sci. 16:11728–11749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hara Y, Yano H, Yamaguchi R and Iwasaki K: Surgical excision of a lactating adenoma with rapid enlargement: A case report. Int J Surg Case Rep. 89:1065442021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niu J, Ma J, Guan X, Zhao X, Li P and Zhang M: Correlation between doppler ultrasound blood flow parameters and angiogenesis and proliferation activity in breast cancer. Med Sci Monit. 25:7035–7041. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar A, Srivastava V, Singh S and Shukla RC: Color doppler ultrasonography for treatment response prediction and evaluation in breast cancer. Future Oncol. 6:1265–1278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Braden AM, Stankowski RV, Engel JM and Onitilo AA: Breast cancer biomarkers: Risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des. 20:4879–4898. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hasanzadeh M, Solhi E, Jafari M, Mokhtarzadeh A, Soleymani J, Jouyban A and Mahboob S: Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast cancer cell lysates and unprocessed human plasma using gold nanoparticles doped on the structure of mesoporous silica. Int J Biol Macromol. 120((Pt B)): 2493–2508. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang S, Wei L, Sun Y, Zhou F, Zhu S, Yang R, Huang Y, Zhang H, Xu H and Yang J: CA153 in breast secretions as a potential molecular marker for diagnosing breast cancer: A meta analysis. PLoS One. 11:e01630302016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asif HM, Sultana S, Ahmed S, Akhtar N and Tariq M: HER-2 positive breast cancer-a mini-review. Asian Pac J Cancer Prev. 17:1609–1615. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB and Gown AM: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 291:1972–1977. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grabowska MM and Day ML: Soluble E-cadherin: More than a symptom of disease. Front Biosci (Landmark Ed). 17:1948–1964. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu QP, Kuang JY, Yang QK, Bian XW and Yu SC: Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. Int J Cancer. 138:2804–2812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren H, Shen Z, Shen J and Zhang Y and Zhang Y: Diagnostic value of Doppler ultrasound parameters combined with MMP-11 in early breast cancer and benign breast diseases. Oncol Lett. 20:1028–1032. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shao Y, Sun X, He Y, Liu C and Liu H: Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 10:e01338302015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeiwar MM, Zaki SM, Mohammad LA, Zidan AA and El Nagar MR: HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients. Egypt J Immunol. 14:29–41. 2007.PubMed/NCBI
|
|
21
|
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, et al: WHO classification of tumours editorial board. The 2019 World health organization classification of tumours of the breast. Histopathology. 77:181–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leng X, Huang G, Li S, Yao M, Ding J and Ma F: Correlation of breast cancer microcirculation construction with tumor stem cells (CSCs) and epithelial-mesenchymal transition (EMT) based on contrast-enhanced ultrasound (CEUS). PLoS One. 16:e02611382021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H and Kianmehr M: Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol. 233:5200–5213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C and Pierga JY: Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: A prospective observational study. Breast Cancer Res. 14:R292012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zaleska-Dorobisz U, Kaczorowski K, Pawluś A, Puchalska A and Inglot M: Ultrasound elastography-review of techniques and its clinical applications. Adv Clin Exp Med. 23:645–655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, et al: Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 162:157–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bae MS, Seo M, Kim KG, Park IA and Moon WK: Quantitative MRI morphology of invasive breast cancer: Correlation with immunohistochemical biomarkers and subtypes. Acta Radiol. 56:269–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li F, Li S, Wei L, Liang X, Zhang H and Liu J: The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers. 18:632–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng H, Zhong A, Xie S, Wang Y, Sun J, Zhang J, Tong Y, Chen M, Zhang G, Ma Q, et al: Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression. Cancer Med. 8:679–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A, Vilgrain I and Bachelot T: Soluble VE-cadherin in metastatic breast cancer: An independent prognostic factor for both progression-free survival and overall survival. Br J Cancer. 116:356–361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JS, Park S, Park JM, Cho JH, Kim SI and Park BW: Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers. Breast Cancer Res Treat. 141:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I and Stieber P: Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res. 27((4A)): 1963–1968. 2007.PubMed/NCBI
|
|
33
|
Di Gioia D, Heinemann V, Nagel D, Untch M, Kahlert S, Bauerfeind I, Koehnke T and Stieber P: Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC). Tumour Biol. 32:777–785. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou BY, Wang LF, Yin HH, Wu TF, Ren TT, Peng C, Li DX, Shi H, Sun LP, Zhao CK and Xu XH: Decoding the molecular subtypes of breast cancer seen on multimodal ultrasound images using an assembled convolutional neural network model: A prospective and multicentre study. EBioMedicine. 74:1036842021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McDonald ES, Clark AS, Tchou J, Zhang P and Freedman GM: Clinical diagnosis and management of breast cancer. J Nucl Med. 57 Suppl 1:9S–16S. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song X, Liang B, Wang C and Shi S: Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer. Exp Ther Med. 20:1822–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thriveni K, Deshmane V, Ramaswamy G and Krishnamoorthy L: Diagnostic significance of CA15-3 with combination of HER-2/neu values at 85th percentiles in breast cancer. Indian J Clin Biochem. 28:136–140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brouxhon SM, Kyrkanides S, Teng X, O'Banion MK, Clarke R, Byers S and Ma L: Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 53:893–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grewal DS, Bhanu KU, Sahni H, Maheshwari S, Kakria N, Mishra PS and Anand V: Role of qualitative contrast-enhanced ultrasound in the diagnosis of malignant breast lesions. Med J Armed Forces India. 79:414–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao YX, Liu S, Hu YB, Ge YY and Lv DM: Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: A retrospective study. Onco Targets Ther. 10:1123–1129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin ZM, Wang TT, Zhu JY, Xu YY, Chen F and Huang PT: A nomogram based on combining clinical features and contrast enhanced ultrasound is not able to identify Her-2 over-expressing cancer from other breast cancers. Front Oncol. 13:10356452023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moelans CB, de Weger RA, Van der Wall E and van Diest PJ: Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol. 80:380–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumari L, Mishra L, Patel P, Sharma N, Gupta GD and Kurmi BD: Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer. J Drug Target. 31:889–907. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Smolanka II, Bagmut IY, Movchan OV, Sheremet MI, Bilyi OM, Lyashenko AO, Dosenko IV, Loboda AD, Ivankova OM and Kolisnyk IL: Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics. J Med Life. 16:153–159. 2023. View Article : Google Scholar : PubMed/NCBI
|
